Abstract:
Prostate cancer is the second leading cause of cancer death in North America, and becomes significant in Europe and Asia, Hormonal therapy, the current remedy for metastatic prostate cancer is not curative and causes various adverse effects. We established cell-based assays to test new treatment for androgen-independent cancer. Also, we discover administration of wedelolactone (reagent) by targeting IKKα (therapeutic target) as a highly effective way to block androgen receptor activity and control prostatet cancer growth. The disclosure is valuable in drug discovery and androgen-regulated diseases, including prostate cancer, benign prostate hypertrophy, breast cancer, boldness, acnes, osteoporosis, frignidness, oily skin, etc.
Fields of Application:
1. Drug discovery for prostate cancer and benign prostate hypertrophy. 2. As therapeutics for prostate cancer and benign prostate hypertrophy. 3. Detecting toxin and environmental hormones 4. Additional androgen-regulated diseases, e.g. breast cancer, boldness, acnes, osteoporosis, frigidness, oily skin, etc.
Advantages when compared to the existing technologies:
1. The cell-based functional assay for androgen receptor is more relevant than conventional ligand-receptor binding assay, or receptor-coactivaotr interaction assays 2. The cell-based functional assay for androgen receptro is high-throughput. 3. Xenograft of 22Rv/PSA 36-103 cell line in nude mice can grow into prostate tumors and applicable to molecular imaging in vivo via bioluminescence. There is no such celll line whose luciferase is under androgen regulation. 4. There is no proved therapy for hormone-refractory prostate cancer. And, we prospose use of wedelolactone and IKKα inhibitors to control the advanced prostate cancer.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
IP Status:US 8597701 CN 101313926B TW I 324521 TW I 405966 US 9144591B2
